Inventor · disambiguated record
Kipp Andrew Weiskopf
Also filed as: WEISKOPF KIPP · WEISKOPF KIPP ANDREW
25 granted patents·8 pending applications·178 citations·filing 2013–2025
96Inventor score
Top patents by PatentIndex Score
33 records- 0196US11608377B2Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonistUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Mar 21, 2023·7 cites·15 claims
- 0296US11208481B2High affinity SIRP-alpha reagents and methods of usingUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Dec 28, 2021·7 cites·28 claims
- 0396US10781256B2Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodiesUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Sep 22, 2020·14 cites·14 claims
- 0496US10081680B2Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodiesUNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Sep 25, 2018·42 cites·15 claims
- 0595US10723803B2CD47 targeted therapies for the treatment of infectious diseaseUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Jul 28, 2020·8 cites·13 claims
- 0695US9944911B2High affinity Sirp-alpha reagents and methods of usingUNIV LELAND STANFORD JUNIOR·Filed 2013·Granted Apr 17, 2018·23 cites·15 claims
- 0794US10316094B2Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistanceUNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Jun 11, 2019·9 cites·17 claims
- 0893US12030944B2Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonistUNIV LELAND STANFORD JUNIOR·Filed 2023·Granted Jul 9, 2024·1 cites·22 claims
- 0993US10406179B2Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signalingUNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Sep 10, 2019·16 cites·15 claims
- 1092US12195532B2High affinity SIRP-alpha reagents and methods of usingUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Jan 14, 2025·1 cites·10 claims
- 1192US11780931B2CD47 targeted therapies for the treatment of infectious diseaseUNIV LELAND STANFORD JUNIOR·Filed 2021·Granted Oct 10, 2023·1 cites·28 claims
- 1292US10894831B2Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonistUNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Jan 19, 2021·8 cites·18 claims
- 1391US10184004B2CD47 targeted therapies for the treatment of infectious diseaseUNIV LELAND STANFORD JUNIOR·Filed 2017·Granted Jan 22, 2019·7 cites·13 claims
- 1491US9945870B2Methods for determining responsiveness to an anti-CD47 agentUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Apr 17, 2018·9 cites·20 claims
- 1591US9771428B2CD47 targeted therapies for the treatment of infectious diseaseUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Sep 26, 2017·11 cites·10 claims
- 1690US11230607B2CD47 targeted therapies for the treatment of infectious diseaseUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Jan 25, 2022·2 cites·15 claims
- 1789US2025223355A1High affinity sirp-alpha reagents and methods of usingUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 1886US11419897B2Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signalingUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Aug 23, 2022·2 cites·16 claims
- 1984US10064925B2Use of anti-CD47 agents to enhance immunizationUNIV LELAND STANFORD JUNIOR·Filed 2014·Granted Sep 4, 2018·7 cites·4 claims
- 2083US12410259B2CD47 targeted therapies for the treatment of infectious diseaseUNIV LELAND STANFORD JUNIOR·Filed 2023·Granted Sep 9, 2025·0 cites·19 claims
- 2183US2024400688A1Enhanced depletion of targeted cells with cd47 blockade and an immune costimulatory agonistUNIV LELAND STANFORD JUNIOR·Filed 2024·Application pending·0 cites
- 2280US12233093B2Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signalingUNIV LELAND STANFORD JUNIOR·Filed 2022·Granted Feb 25, 2025·0 cites·17 claims
- 2380US10889649B2Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistanceUNIV LELAND STANFORD JUNIOR·Filed 2019·Granted Jan 12, 2021·2 cites·58 claims
- 2473US2025249042A1Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signalingUNIV LELAND STANFORD JUNIOR·Filed 2025·Application pending·0 cites
- 2572US11459388B2Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistanceUNIV LELAND STANFORD JUNIOR·Filed 2020·Granted Oct 4, 2022·0 cites·20 claims
- 2669US11046763B2Targeted therapy for small cell lung cancerUNIV LELAND STANFORD JUNIOR·Filed 2015·Granted Jun 29, 2021·1 cites·7 claims
- 2765US2025228938A1The combination of macrophage-directed immunotherapy and targeted agents for treatment of cancerWHITEHEAD INST BIOMEDICAL RES·Filed 2023·Application pending·0 cites
- 2864US11154600B2Use of anti-CD47 agents to enhance immunizationUNIV LELAND STANFORD JUNIOR·Filed 2018·Granted Oct 26, 2021·0 cites·5 claims
- 2964US2025145726A1Innate immune checkpoint modulatorsWHITEHEAD INST BIOMEDICAL RES·Filed 2023·Application pending·0 cites
- 3063US2025180543A1Compositions and methods of a high-throughput screen to identify compounds that alter macrophage-mediated cytotoxicity of target cellsWHITEHEAD INST BIOMEDICAL RES·Filed 2023·Application pending·0 cites
- 3159US2021277115A1Targeted therapy for small cell lung cancerUNIV LELAND STANFORD JUNIOR·Filed 2021·Application pending·0 cites
- 3252US10358472B2High affinity CD47 analogsUNIV LELAND STANFORD JUNIOR·Filed 2016·Granted Jul 23, 2019·0 cites·12 claims
- 3338US2017157296A1Macrophage or monocyte enhanced wound healingUNIV LELAND STANFORD JUNIOR·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kipp Andrew Weiskopf files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →